History and Mission

CORAT Therapeutics GmbH is a biopharmaceutical company founded in June 2020 as a spin off from the recombinant antibody development company Yumab GmbH. The company is dedicated to develop therapeutic products to fight SARS-CoV-2 mediated Covid-19 disease and help to cure Covid-19 affected people suffering from this disease.

The company is located in Braunschweig (Germany) and is co-funded by the Lower Saxony State NBank and private investors with a first financing round. The company is currently on the way to conduct a second financing to achieve the next milestones, i.e. performance of clinical studies to get a conditional market approval in early 2022 and to prepare the commercial manufacturing process to be ready to supply the drug to treat Covid-19 affected patients.

Our lead product COR-101 is a fully human, SARS-CoV-2 neutralizing antibody blocking the interaction of the virus with its cellular receptor and thereby immediately stopping the virus spreading within the human body. In contrast to vaccines, COR-101 will be clinically evaluated not only for prevention of infection, but for treatment of infected patients and cure of the disease.